StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Biopharma Segment by Quarter

Biopharma Segment — Research & development expenses ($M) ($M)

QuarterlyAnnual

Pfizer Biopharma Segment: $2,376M in Q2 2026, up 12.7% from a year earlier.

Latest, Q2 2026
2,376
Period ended Jun 28, 2026
Change on a year earlier
+12.7%
2,109 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Note 17 — Segment Reporting (ASU 2023-07 Significant Segment Expenses).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBiopharma Segment — Research & development expenses ($M) ($M)Year on yearSource
Q2 2026Jun 28, 20262,376+12.7%Form 10-Q (filed 2026-08-04) ↗
Q1 2026Mar 29, 20262,137+10.1%Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 20252,948+7.9%Form 10-K (filed 2026-02-26) ↗
Q3 2025Sep 28, 20252,185-7.2%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 29, 20252,109-8.0%Form 10-Q (filed 2026-08-04) ↗
Q1 2025Mar 30, 20251,941-9.8%Form 10-Q (filed 2026-05-05) ↗
Q4 2024Dec 31, 20242,733–Form 10-K (filed 2026-02-26) ↗
Q3 2024Sep 29, 20242,355–Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 20242,293–Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 20242,151–Form 10-Q (filed 2025-05-05) ↗

Cite this data

StockData. (2026). Pfizer Biopharma Segment ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/seg-rd-bio

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.